| Literature DB >> 31085741 |
Masafumi Kurajoh1, Shinya Fukumoto2, Masanori Emoto1, Takayo Murase3, Takashi Nakamura3, Takuma Ishihara4, Hirofumi Go5, Kouji Yamamoto6, Shinya Nakatani1, Akihiro Tsuda1, Shinsuke Yamada1, Tomoaki Morioka1, Katsuhito Mori7, Yasuo Imanishi1, Masaaki Inaba1,7.
Abstract
Background We developed a novel high-sensitive assay for plasma xanthine oxidoreductase (XOR) activity that is not affected by the original serum uric acid level. However, the association of plasma XOR activity with that level has not been fully examined. Methods This cross-sectional study included 191 subjects (91 males, 100 females) registered in the MedCity21 health examination registry. Plasma XOR activity was determined using our assay for plasma XOR activity with [13C2,15N2] xanthine and liquid chromatography/triple quadrupole mass spectrometry. Serum levels of uric acid and adiponectin, and visceral fat area (VFA) obtained by computed tomography were measured, and insulin resistance was determined based on the homeostasis model assessment (HOMA-IR) index. Results The median values for uric acid and plasma XOR activity were 333 μmol/L and 26.1 pmol/h/mL, respectively. Multivariable linear regression analysis showed a significant and positive association of serum uric acid level (coefficient: 26.503; 95% confidence interval: 2.06, 50.945; p = 0.035) with plasma XOR activity independent of VFA and HOMA-IR, and also age, gender, alcohol drinking habit, systolic blood pressure, estimated glomerular filtration rate (eGFR), glycated hemoglobin A1c, triglyceride, and adiponectin levels. The "gender*XOR activity" interaction was not significant (p = 0.91), providing no evidence that gender modifies the relationship between plasma XOR activity and serum uric acid level. Conclusions Plasma XOR activity was found to be positively associated with serum uric acid level independent of other known confounding factors affecting that level, including gender difference, eGFR, adiponectin level, VFA, and HOMA-IR.Entities:
Keywords: insulin resistance; plasma XOR activity; uric acid; visceral obesity
Mesh:
Substances:
Year: 2020 PMID: 31085741 DOI: 10.1515/cclm-2019-0199
Source DB: PubMed Journal: Clin Chem Lab Med ISSN: 1434-6621 Impact factor: 3.694